|20th November 2020||Scott D Sandell||69,564||Open or private sale||$67.27||$4,679,507.67|
|20th November 2020||Scott D Sandell||97||Open or private sale||$65.64||$6,367.08|
|19th November 2020||Richard J Rodgers||17,730||Open or private purchase||$0.00|
|19th November 2020||Scott D Sandell||267,743||Open or private sale||$65.84||$17,626,913.95|
|18th November 2020||Scott D Sandell||51,428||Open or private sale||$65.53||$3,369,871.13|
|17th November 2020||Scott D Sandell||312,171||Open or private sale||$65.62||$20,484,879.54|
|16th November 2020||Scott D Sandell||86,980||Open or private sale||$64.24||$5,587,751.76|
|13th November 2020||Scott D Sandell||20,578||Other acquisition or disposition||$0.00|
|13th November 2020||Scott D Sandell||165,945||Other acquisition or disposition||$0.00|
|13th November 2020||Scott D Sandell||2,500,000||Other acquisition or disposition||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Ardelyx, Inc. focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development.